A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-12
DOI
10.3389/fneur.2020.00818
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
- (2020) Tony Sehr et al. Frontiers in Neurology
- Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod
- (2019) Emilio Vanoli et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
- (2018) Duygu Kocyigit et al. Multiple Sclerosis and Related Disorders
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis
- (2017) Katja Thomas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Heart rate variability decreases after 3 months of sustained treatment with fingolimod
- (2017) Jochen Vehoff et al. JOURNAL OF NEUROLOGY
- Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
- (2017) Kai Li et al. Frontiers in Neuroscience
- Early safety and efficacy of fingolimod treatment in Denmark
- (2016) A. Voldsgaard et al. ACTA NEUROLOGICA SCANDINAVICA
- The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis
- (2016) Joe Datt et al. Multiple Sclerosis and Related Disorders
- Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation
- (2016) Sakari Simula et al. Multiple Sclerosis and Related Disorders
- Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
- (2015) Laura Ordoñez-Boschetti et al. ADVANCES IN THERAPY
- The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue
- (2015) Emmanuel E. Egom et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Effects of Three Months Fingolimod Therapy on Heart Rate
- (2015) Sakari Simula et al. Journal of Neuroimmune Pharmacology
- Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis
- (2015) Sakari Simula et al. Multiple Sclerosis Journal
- Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis
- (2015) Sakari Simula et al. Multiple Sclerosis Journal
- Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors
- (2015) R.A. Bermel et al. Multiple Sclerosis and Related Disorders
- Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
- (2014) John Camm et al. AMERICAN HEART JOURNAL
- Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
- (2014) Alice Laroni et al. BMC Neurology
- Vagomimetic Effects of Fingolimod: Physiology and Clinical Implications
- (2014) Emilio Vanoli et al. CNS Neuroscience & Therapeutics
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- The autonomic balance predicts cardiac responses after the first dose of fingolimod
- (2014) S Rossi et al. Multiple Sclerosis Journal
- Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia
- (2014) C. Warnke et al. NEUROLOGY
- First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
- (2014) John P. DiMarco et al. Multiple Sclerosis and Related Disorders
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
- (2013) Ralf Gold et al. JOURNAL OF NEUROLOGY
- Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod
- (2013) Paul Schurmann et al. Multiple Sclerosis and Related Disorders
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects
- (2008) John M. Kovarik et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More